Prothena Reports Strong Q1 Net Income Driven by $50M Coramitug Milestone, Advances Key Clinical Programs

summarizeSummary

Prothena reported a net income of $32.7 million in Q1 2026, a significant reversal from a prior-year loss, fueled by a $50 million milestone payment for its Coramitug program and positive operating cash flow, alongside continued advancement of its clinical pipeline.

check_boxKey Events

• Achieved Q1 Net Income of $32.7 Million

  The company reported a net income of $32.7 million for the three months ended March 31, 2026, a substantial improvement from a net loss of $60.2 million in the same period last year.

• Received $50 Million Coramitug Milestone Payment

  Revenue was significantly boosted by a $50 million development milestone payment from Novo Nordisk related to the advancement of coramitug in its Phase 3 CLEOPATTRA clinical trial.

• Generated Positive Operating Cash Flow

  Net cash provided by operating activities was $28.9 million for Q1 2026, a strong turnaround from $53.4 million used in operating activities in Q1 2025.

• Advanced Multiple Clinical Programs

  Key pipeline updates include the initiation of Phase 3 trials for Prasinezumab (Parkinson's) and Coramitug (ATTR amyloidosis), and Fast Track designations for Coramitug and BMS-986446 (Alzheimer's).

auto_awesomeAnalysis

Prothena has reported a significant financial turnaround in Q1 2026, moving from a substantial net loss in the prior year to a net income of $32.7 million. This positive shift was primarily driven by a $50 million development milestone payment from Novo Nordisk for the continued advancement of coramitug in its Phase 3 clinical trial. The company also demonstrated a strong improvement in operational efficiency, generating $28.9 million in cash from operations compared to a significant cash burn in the prior year. This financial strength, coupled with ongoing progress in multiple late-stage clinical programs and a continued share repurchase program, signals robust operational execution and a positive outlook for investors.